Vessi Medical is an innovative brand that is revolutionizing the treatment of Non Muscle Invasive Bladder Cancer (NMIBC) with their unique cryo spray. This cutting-edge technology offers a new approach to target hollow and humid organs, providing a solution that is both efficient and effective. Currently, Vessi's device is undergoing clinical studies and is not yet available for sale.

However, their groundbreaking cryo spray has already shown promise in treating low-grade NMIBC, which accounts for approximately 50% of bladder cancer patients. The standard treatment for NMIBC, Transurethral Resection of Bladder Tumor (TURBT), is a costly and invasive surgical procedure performed under general anesthesia. It often leads to complications and requires multiple repeat procedures, significantly reducing patients' quality of life.

Vessi's bladder-specific cryotherapy aims to reduce these complications and offer a minimally invasive alternative to surgery. With easy-to-use features, the Vessi system consists of a standalone console and a disposable device inserted transurethrally into the bladder. This allows for visualization in liquid and gas environments, making the treatment process more efficient and accurate.

Led by a team of experienced professionals in the medical device industry and with the guidance of renowned scientific advisors, Vessi Medical is at the forefront of advancing bladder cancer treatment. Stay tuned for the availability of their groundbreaking cryo spray as they continue their mission to improve the lives of bladder cancer patients worldwide